Health Management Associates HMA reported Q3:10 adjusted EPS from continuing operations of $0.14, compared
to Oppenheimer's estimate and the Street consensus of $0.12.
Overall this was a solid quarter across the board as the company was able to overcome a tough comp and beat expectations. More importantly, bad debt expense of 12.6% fell 20 bps YoY and was in line with our estimate. As a result of the strong quarter, the company raised its 2010 EPS guidance to $0.64-0.66 from the previous $0.56-0.61.
HMA generated strong FCF ($67.3M), which was used to acquire the 413-bed Wuesthoff Health System for ~$152M, effective October 1. The company's acquisition pipeline remains robust and HMA is currently reviewing several
opportunities similar to the Wuesthoff transaction in terms of scope and size.
Oppenheimer has a Perform rating on HMA
HMA is trading higher at $7.76
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in